Çocuk Nöroloji Hastalarında İlaç Erüpsiyonları

1. Mori F, Blanca-Lopez N, Caubet JC et al. Delayed hypersensitivity to antiepileptic drugs in children. Pediatr Allergy Immunol 2021;32(3):425-36.
Noguera-Morel L, Hernández-Martín Á, Torrelo A. Cutaneous drug reactions in the pediatric population. Pediatr Clin North Am. 2014;61(2):403-26.
Stern RS. Clinical practice. Exanthematous drug eruptions. N Engl J Med 2012;366(26):2492-501.
Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics. 2007;120(4):1082-96.
Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765-70.
Deacock SJ. An approach to the patient with urticaria. Clin Exp Immunol. 2008;153(2):151-61.
Demoly P, Adkinson NF, Brockow K et al. International Consensus on drug allergy. Allergy. 2014;69(4):420-37.
Mortureux P, Léauté-Labrèze C, Legrain-Lifermann V, Lamireau T, Sarlangue J, Taïeb A. Acute urticaria in infancy and early childhood: a prospective study. Arch Dermatol. 1998;134(3):319-23.
Song JE, Sidbury R. An update on pediatric cutaneous drug eruptions. Clin Dermatol. 2014;32(4):516-23.
Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Demographic and clinical profiles in patients with acute urticaria. Allergol Immunopathol (Madr). 2015;43(4):409-15.
Poon M, Reid C. Do steroids help children with acute urticaria? Arch Dis Child. 2004;89(1):85-86.
Lawley TJ, Bielory L, Gascon P, Yancey KB, Young NS, Frank MM. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med.1984;311(22):1407-13.
Frieling GW. Pediatric Drug Eruptions of the Skin. In: Hall JC, Hall BJ, editors. Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. London: Springer London; 2015:431-44.
Guvenir H, Arikoglu T, Vezir E, Misirlioglu ED. Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions. Curr Pharm Des. 2019;25(36):3840-54.
Yorulmaz A, Akın F, Sert A, Ağır MA, Yılmaz R, Arslan Ş. Demographic and clinical characteristics of patients with serum sickness-like reaction. Clin Rheumatol. 2018;37(5):1389-94.
King BA, Geelhoed GC. Adverse skin and joint reactions associated with oral antibiotics in children: the role of cefaclor in serum sickness-like reactions. J Paediatr Child Health. 2003;39(9):677-81.
Shin HT, Chang MW. Drug eruptions in children. Curr Probl Pediatr. 2001;31(7):207-34.
Levine LR. Quantitative comparison of adverse reactions to cefaclor vs. amoxicillin in a surveillance study. Pediatr Infect Dis. 1985;4(4):358-61.
Apisarnthanarak A, Uyeki TM, Miller ER, Mundy LM. Serum sickness-like reaction associated with inactivated influenza vaccination among Thai health care personnel: risk factors and outcomes. Clin Infect Dis. 2009;49(1):18-22.
Arkachaisri T. Serum sickness and hepatitis B vaccine including review of the literature. J Med Assoc Thai. 2002;85(2):607-12.
Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy. 2007;37(7):989-99.
Atanaskovic-Markovic M, Tsabouri S. Exanthematous reactions to drugs in children. Curr Opin Allergy Clin Immunol. 2021;21(4):335-39.
Feldmeyer L, Heidemeyer K, Yawalkar N. Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy. Int J Mol Sci. 2016;17(8).
Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007;157(5):989-96.
Anderson HJ, Lee JB. A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption. Medicina (Kaunas). 2021;57(9).
Patel S, John AM, Handler MZ, Schwartz RA. Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption. Am J Clin Dermatol. 2020;21(3):393 99.
Kanwar AJ, Dhar S, Ghosh S, Kaur S. Mucosal fixed drug eruption. Dermatology. 1994;188(2):171.
Nguyen E, Gabel CK, Yu J. Pediatric drug eruptions. Clin Dermatol. 2020;38(6):629-40.
Bhargava NC, Singh G. Fixed eruption due to two unrelated drugs: oxyphenbutazone and tetracycline. Int J Dermatol. 1981;20(6):435.
Soares A, Sokumbi O. Recent Updates in the Treatment of Erythema Multiforme. Medicina (Kaunas). 2021;57(9).
Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current Perspectives on Erythema Multiforme. Clin Rev Allergy Immunol. 2018;54(1):177-84.
Zoghaib S, Kechichian E, Souaid K, Soutou B, Helou J, Tomb R. Triggers, clinical manifestations, and management of pediatric erythema multiforme: A systematic review. Clin Rev Allergy Immunol. 2019;81(3):813-22.
Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 2012;51(8):889-902.
Merrill ED, Stanford CW. Erythema Multiforme and Drug Reactions. In: Hall JC, Hall BJ, editors. Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. London: Springer London; 2015:65-76.
Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994;102(6):28-30
Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131(5):539-43.
Kohanim S, Palioura S, Saeed HN et al. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-A Comprehensive Review and Guide to Therapy. I. Systemic Disease. Ocul Surf. 2016;14(1):2-19.
Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-96.
Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147-76.
Goodman H. Nikolsky sign; page from notable contributors to the knowledge of dermatology. AMA Arch Derm Syphilol. 1953;68(3):334-35.
Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas). 2021;57(9).
Charlton OA, Harris V, Phan K, Mewton E, Jackson C, Cooper A. Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review. Adv Wound Care (New Rochelle). 2020;9(7):426-39.
Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J Invest Dermatol. 2016;136(7):1387-97.
Schneider JA, Cohen PR. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Adv Ther. 2017;34(6):1235-44.
Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(2):187
Cardones AR. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clin Dermatol. 2020;38(6):702-11.
Peter JG, Lehloenya R, Dlamini S et al. Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. J Allergy Clin Immunol Pract. 2017;5(3):547-63.
Lehloenya RJ, Peter JG, Copascu A, Trubiano JA, Phillips EJ. Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go? J Allergy Clin Immunol Pract. 2020;8(9):2878-95
Momen SE, Diaz-Cano S, Walsh S, Creamer D. Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms: Facial edema aligns to the severe phenotype. J Am Acad Dermatol. 2021;85(3):645-52.
White KD, Abe R, Ardern-Jones M et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translation. J Allergy Clin Immunol Pract. 2018;6(1):38-69.
Kano Y, Tohyama M, Aihara M et al. Sequelae in 145 patients with drug‐induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR). J Dermatol. 2015;42(3):276-82.
Kardaun SH, Sidoroff A, Valeyrie-Allanore L et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609-11.
Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int. 2019;68(3):301-08.
Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Short-and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2013;68(5):721-28.
Giri PP, Roy S, Bhattyacharya S, Pal P, Dhar S. Dress syndrome with sepsis, acute respiratory distress syndrome and pneumomediastinum. Indian J Dermatol. 2011;56(6):763.